|
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
TLX1- or TLX3-deregulated T-cell acute lymphoblastic leukemias (T-ALL; TLX1/3<sup>+</sup>) share an immature cortical phenotype and similar transcriptional signatures.
|
30659025 |
2019 |
|
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Homeobox protein TLX3 activates miR-125b expression to promote T-cell acute lymphoblastic leukemia.
|
29296717 |
2017 |
|
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
NKX2-5, SIL/TAL and TLX3/HOX11L2 expression in Egyptian pediatric T-cell acute lymphoblastic leukemia.
|
24571118 |
2016 |
|
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Our results suggested that TLX3 expression is not an indicator for the prognosis of pediatric T-ALL.
|
24997618 |
2014 |
|
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
|
0.400 |
FusionGene
|
disease |
ORPHANET |
Hijacking T cell differentiation: new insights in TLX function in T-ALL.
|
22516255 |
2012 |
|
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
|
0.400 |
FusionGene
|
disease |
ORPHANET |
TLX homeodomain oncogenes mediate T cell maturation arrest in T-ALL via interaction with ETS1 and suppression of TCRα gene expression.
|
22516263 |
2012 |
|
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The most common recurrent cytogenetic abnormalities in T-lymphoblastic leukemia (T-acute lymphoblastic leukemia [T-ALL]) involve T-cell receptor (TCR) loci and a variety of partner genes, including HOX11, HOX11L2, MYC, and TAL1.
|
22563559 |
2012 |
|
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Overall, these results place TLX1 and TLX3 at the top of an oncogenic transcriptional network controlling leukemia development, show the power of network analyses to identify key elements in the regulatory circuits governing human cancer and identify RUNX1 as a tumor-suppressor gene in T-ALL.
|
22366949 |
2012 |
|
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
IL7R mutations induce a gene expression profile partially resembling that provoked by IL-7 and are enriched in the T-ALL subgroup comprising TLX3 rearranged and HOXA deregulated cases.
|
21892159 |
2011 |
|
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
These cases generally lacked overexpression of the TAL1, HOX11, HOX11L2, or the HOXA cluster genes, which have been used to define separate molecular pathways leading to T-ALL.
|
20124220 |
2010 |
|
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Although molecular disease was frequently present after a 4-drug induction therapy, final treatment outcome was excellent indicating that TLX3+ T-ALL cases may benefit from a BFM-type of ALL therapy with early and late re-intensification elements.
|
19821827 |
2010 |
|
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Mutually exclusive oncogenic rearrangements may delineate specific T-cell acute lymphoblastic leukaemia (T-ALL) subgroups, and so far at least 4 molecular-cytogenetic subgroups have been identified, i.e. the TAL/LMO, the TLX1/HOX11, the TLX3/HOX11L2 and the HOXA subgroups.
|
21112032 |
2010 |
|
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
SIL-TAL1 fusion gene and the ectopic expression of HOX11L2 are common molecular abnormalities in T-cell acute lymphoblastic leukemia (T-ALL).
|
19562638 |
2009 |
|
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Three members of the NK-like subfamily of homeobox genes (NKLs), TLX1, TLX3 and NKX2-5, are implicated in T-cell acute lymphoblastic leukemia (T-ALL).
|
19835636 |
2009 |
|
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
This study provides a genome-wide overview of copy number changes in TLX3 rearranged T-ALL and offers great new challenges for the identification of new target genes that may play a role in the pathogenesis of T-ALL.
|
18185524 |
2008 |
|
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Patients with T-cell acute lymphoblastic leukemia positive for TLX3 had a poorer survival compared to those with T-ALL negative for TLX3 (overall survival: 45+/-11% vs. 57+/-5%, p=0.049).
|
18835836 |
2008 |
|
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
|
0.400 |
GeneticVariation
|
disease |
LHGDN |
This study provides a genome-wide overview of copy number changes in TLX3 rearranged T-ALL and offers great new challenges for the identification of new target genes that may play a role in the pathogenesis of T-ALL.
|
18185524 |
2008 |
|
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Activation of TLX3 and NKX2-5 in t(5;14)(q35;q32) T-cell acute lymphoblastic leukemia by remote 3'-BCL11B enhancers and coregulation by PU.1 and HMGA1.
|
17308084 |
2007 |
|
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The full characterization of the TLX3 transcription regulation will ultimately provide crucial elements to define the involvement of this gene in T-cell acute lymphocytic leukemia development.
|
16966433 |
2006 |
|
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
This was associated with an inferior OS for HOX11L2 T-ALLs (13% vs 47% in HOX11L2-T-ALLs; P = .009).
|
15637138 |
2005 |
|
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
We investigated the prognostic effect of the expression levels of eight oncogenic transcription factors--TLX1 (HOX11), TLX3 (HOX11L2), TAL1, TAL2, LYL1, OLIG2 (BHLHB1), LMO1, and LMO2--in 52 adults with T-cell acute lymphoblastic leukaemia.
|
14975618 |
2004 |
|
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
This study further underscores that TLX3 expression in T-ALL is strongly associated with the presence of genomic rearrangements.
|
15334547 |
2004 |
|
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
We did not identify cases with a t(5;14)(q35;q32) involving CSX, but we did identify 5 cases of t(5;14) involving HOX11L2 out of 32 T-ALL cases studied; in each case the 14q32 breakpoint was found to be centromeric to the IGH region.
|
15194534 |
2004 |
|
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Our results also show that HOX11L2 expression essentially occurs as a result of a 5q35 rearrangement, but is not associated with another identified T-ALL specific recurrent genetic abnormality, such as SIL-TAL fusion or HOX11 expression.
|
12970786 |
2003 |
|
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Cytogenetic analysis of a pediatric T-cell acute lymphoblastic leukemia (ALL) cell line (HPB-ALL) revealed the cryptic t(5;14)(q35;q32.2), recently found in 15-20% pediatric T-ALL patients, with 5q35 and 14q32.2 breakpoints at 5'-HOX11L2 and 3'-BCL11B, respectively.
|
12661009 |
2003 |